首页> 外国专利> Hypermethylation biomarkers for detection of cervical cancer

Hypermethylation biomarkers for detection of cervical cancer

机译:用于检测子宫颈癌的高甲基化生物标志物

摘要

Pap smears and HPV infection tests do not distinguish between lesions that will progress to an invasive carcinoma and those that will not. We aimed to identify epigenetic biomarkers for diagnosis and progression monitoring of premalignant lesions in cervical cancer. Hypermethylated genes were identified as potential biomarkers after validation by MSP, including GGTLA4 and ZNF516. The methylation frequency for these two genes was higher in tumor: GGTLA4 (100%) and ZNF516 (96%); than in normal samples: GGTLA4 (12%) and ZNF516 (16%). The methylation status of GGTLA4 showed a progression in methylation frequency from normal samples to invasive carcinoma. The immunohistochemical expression was lower in tumor for both: GGTLA4 (50.8%) and ZNF516 (66.2%); than in normal samples: GGTLA4 (71.2%) and ZNF516 (88.1%) (p0.05). In conclusion, we identified methylation biomarkers for the molecular screening and characterization of cervical cancer.
机译:子宫颈抹片检查和HPV感染测试不能区分将发展为浸润性癌的病变和不会发展为浸润性癌的病变。我们旨在鉴定表观遗传生物标志物,以诊断和监测子宫颈癌的癌前病变。经MSP验证后,超甲基化的基因被鉴定为潜在的生物标记,包括GGTLA4和ZNF516。肿瘤中这两个基因的甲基化频率较高:GGTLA4(100%)和ZNF516(96%);比正常样品高:GGTLA4(12%)和ZNF516(16%)。 GGTLA4的甲基化状态显示甲基化频率从正常样品发展为浸润性癌。对于两种肿瘤,GGTLA4(50.8%)和ZNF516(66.2%)的免疫组化表达均较低。与正常样品相比:GGTLA4(71.2%)和ZNF516(88.1%)(p <0.05)。总之,我们确定了用于宫颈癌分子筛查和表征的甲基化生物标志物。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号